Expert Financial Analysis and Reporting

Eyal Desheh is the Chief Financial Officer of Teva. During the recent third quarter conference call, he answered a question from an analyst about the development status of the AB rated generic to EpiPen. He said: “In terms of EpiPen, we are working very closely with the FDA. I haven’t changed my view. My expectation […]

Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 in 2018. The thinking behind this was explained in my April 22, 2016  report “An Outstanding Product Pipeline Promises Dramatic Growth Through 2022” (see this link)  If you are unfamiliar with the Company or need to be refreshed, I would suggest […]

Overview and Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and the thinking behind this was explained in my April 22 report An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92) The stock […]

You cannot turn on the business news channels without hearing extensive comments and condemnation by pundits and politicians about Mylan’s aggressive price hikes on EpiPen. Investors are asking if this could somehow expedite approval of Antares/Teva’s AB rated generic to EpiPen. As far as I know, Teva has not yet submitted a response to the Complete […]

A number of people have asked me if I know of any specific reason for the strength in Antares’s stock following the 2Q, 2016 conference call. The stock reached an inter-day high today of $1.34 today which is a high for the year. For much of the year to date, it has been trading around […]

Teva announced today the launch of its AB rated generic to Imitex (sumatriptan). Remember that Antares books revenues from Teva with a one quarter lag so there should be no revenues reflected from the launch in the 2Q, 2016 report from Antares. Teva will include this product in its bundling agreements for generics with pharmacies […]

Report Overview Antares and AMAG Pharmaceuticals are jointly developing a new subcutaneous formulation of AMAG’s key drug Makena which is currently administered as a deep and painful intra-muscular injection. I recently did a detailed report on the medical profile of Makena and concluded that most (all) of Makena’s sales- estimated at $310 to $340 million […]

Overview I listened to CEO Bob Apple speak at the Deutsche Bank conference and wanted to pass along a few pieces of information that are incremental to my recent report. Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 AB EpiPen In regard to AB EpiPen, he said that they are working with Teva […]

I recently wrote a report on Antares entitled Makena has the Potential to Make a Very Significant Contribution to EPS  that highlighted the potentially  significant impact on Antares’ earnings of the subcutaneous formulation of Makena being developed jointly by Antares and AMAG Pharmaceuticals. In a press release summarizing 1Q, 2016 results, AMAG issued some very positive […]

Investment Thesis in Brief If you like numbers, you will like this report. It is a very detailed analysis of the contribution to Antares sales and profits of 7 new products that will drive growth in coming years. As summarized in the following table, I am looking for Antares to roughly breakeven in 2017 and […]